LifeMD, Inc. Q1 2026 Earnings Call Summary

Strategic Evolution and Performance Drivers

• Achieved record net subscriber growth of 42,000 in Q1, driven by a 120% sequential increase in weight management sign-ups following the launch of oral GLP-1 therapies.

• Strategic pivot from compounded medications to branded GLP-1 therapies is underway to prioritize 'quality revenue' and higher patient retention, despite short-term margin pressure.

• Women's health program grew 7x from its Q4 base, validated by an 80% on-therapy retention rate and a focus on longitudinal care rather than transactional prescriptions.

• Operational leverage is being built through the deployment of AI across clinical decision support and back-office workflows, aiming to increase provider capacity without adding headcount.

• In-house pharmacy fulfillment reached 20,000 prescriptions per month, serving as a primary lever for gross margin expansion which reached 88% in Q1.

• Insurance infrastructure expanded to 112 million covered lives, with management observing that insurance-supported patients show a 10-point improvement in retention over self-pay cohorts.

• Customer acquisition costs (CAC) for weight management improved 4% to 5% sequentially even as daily patient acquisition volumes effectively doubled.

2026 Outlook and Strategic Roadmap

• Reaffirmed full-year 2026 revenue guidance of $220 million to $230 million, with an expected exit run rate exceeding $250 million by Q4.

• Anticipate returning to adjusted EBITDA profitability in the second half of 2026 as customer acquisition costs decline sequentially and the patient volumes added in Q1 become accretive.

• The Medicare GLP-1 bridge program, launching July 1, is identified as a significant catalyst for expanding affordable access to a new demographic in the back half of the year.

• Plans to introduce 7 new compounded pharmacy products focused on hormone and bone health to further scale the women's health category.

• Management expects to reach approximately 230 million covered insurance lives by the end of May 2026, facilitating a shift toward lower-CAC, higher-retention patient profiles.

Operational Context and Risk Factors

• Q1 adjusted EBITDA loss of $4.5 million reflects a deliberate 'investment quarter' with peak marketing spend to capture market share in the GLP-1 category.

• Revenue has been impacted by a strategic shift away from compounded GLP-1 medications toward branded alternatives, a transition the company views as a move toward higher quality revenue streams and long-term collaborations with major pharmaceutical manufacturers.

• Management noted that while insurance patients pay lower platform fees, their lower acquisition costs and higher lifetime value make them more profitable over the long term.

• The company maintains a $30 million undrawn revolving credit facility and $34.5 million in cash to fund ongoing growth initiatives.